利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.024 秒)

    Long Acting Biologically Active Conjugates
    1.
    发明申请
    Long Acting Biologically Active Conjugates 审中-公开
    长效生物活性缀合物

    公开(公告)号：US20070207952A1

    公开(公告)日：2007-09-06

    申请号：US10550715

    申请日：2004-03-24

    申请人： Abelardo Silva ,  John Erickson ,  Michael Eissenstat ,  Elena Afonina ,  Sergei Gulnik

    发明人： Abelardo Silva ,  John Erickson ,  Michael Eissenstat ,  Elena Afonina ,  Sergei Gulnik

    IPC分类号： A61K38/16 ,  A61K38/10 ,  C07K14/47 ,  C07K7/08

    CPC分类号： C07K14/765 ,  A61K38/00 ,  A61K47/643

    摘要： The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.

    摘要翻译： 本发明提供可与大分子如白蛋白反应的生物活性化合物以形成共价连接的络合物，其中所得的复合物在体内显示出所需的生物学活性。 更具体地，复合物是包含与连接基团和蛋白质共价结合的生物活性部分的分离的复合物。 通过将生物活性部分例如肾素抑制剂或病毒融合抑制剂肽与纯化和分离的蛋白质缀合来制备复合物。 与非共轭分子相比，复合物在血液中的寿命延长，与非共轭分子相比，延长的时间段具有生物活性。 本发明还提供了抗病毒化合物，其是病毒感染的抑制剂和/或表现出抗融合生物学特性。 特别地，本发明提供了对人体免疫缺陷病毒（HIV），呼吸道合胞病毒（RSV），人副流感病毒（HPV），麻疹病毒（MeV）和猿猴免疫缺陷病毒（SIV）等病毒具有抑制活性的化合物， 延长了治疗病毒感染的时间。

    ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES
    8.
    发明申请
    ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES 审中-公开
    用于治疗，控制和预防由冠状病毒感染的抗病毒药物

    公开(公告)号：US20070185027A1

    公开(公告)日：2007-08-09

    申请号：US11557983

    申请日：2006-11-09

    申请人： John Erickson ,  Abelardo Silva

    发明人： John Erickson ,  Abelardo Silva

    IPC分类号： A61K38/16 ,  A61K38/10 ,  A61K38/08 ,  C07K7/08 ,  C07K7/06 ,  C07K14/165

    CPC分类号： C07K14/005 ,  A61K38/162 ,  C12N2770/20022

    摘要： The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infaction, in a subject, such as a human subject.

    摘要翻译： 本发明提供可用于预防和治疗受试者冠状病毒感染的组合物和方法。 更具体地，本发明提供了含有阻断冠状病毒例如SARS病毒融合的那些肽和缀合物的肽和缀合物和药物组合物与靶细胞。 这种阻断机制防止或治疗诸如人受试者的受试者中的冠状病毒感染，例如SARS的不适。

    ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES
    9.
    发明申请
    ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES 有权
    用于治疗，控制和预防由冠状病毒感染的抗病毒药物

    公开(公告)号：US20060258577A1

    公开(公告)日：2006-11-16

    申请号：US10833304

    申请日：2004-04-28

    申请人： John Erickson ,  Abelardo Silva

    发明人： John Erickson ,  Abelardo Silva

    IPC分类号： A61K38/16 ,  A61K38/10 ,  A61K38/06 ,  A61K38/08 ,  C07K14/18 ,  C07K7/08 ,  C07K7/06

    CPC分类号： C07K14/005 ,  A61K38/162 ,  C12N2770/20022

    摘要： The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.

    摘要翻译： 本发明提供可用于预防和治疗受试者冠状病毒感染的组合物和方法。 更具体地，本发明提供了含有阻断冠状病毒例如SARS病毒融合的那些肽和缀合物的肽和缀合物和药物组合物与靶细胞。 这种阻断机制防止或治疗诸如人受试者的受试者中的冠状病毒感染，例如SARS感染。

    Antiviral agents for the treatment, control and prevention of infections by coronaviruses
    10.
    发明授权
    Antiviral agents for the treatment, control and prevention of infections by coronaviruses 有权
    用于治疗，控制和预防冠状病毒感染的抗病毒剂

    公开(公告)号：US07151163B2

    公开(公告)日：2006-12-19

    申请号：US10833304

    申请日：2004-04-28

    申请人： John W. Erickson ,  Abelardo Silva

    发明人： John W. Erickson ,  Abelardo Silva

    IPC分类号： C07K14/165 ,  C07K17/00 ,  A61K39/215 ,  A61K39/385

    CPC分类号： C07K14/005 ,  A61K38/162 ,  C12N2770/20022

    摘要： The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.

    摘要翻译： 本发明提供可用于预防和治疗受试者冠状病毒感染的组合物和方法。 更具体地，本发明提供了含有阻断冠状病毒例如SARS病毒融合的那些肽和缀合物的肽和缀合物和药物组合物与靶细胞。 这种阻断机制防止或治疗诸如人受试者的受试者中的冠状病毒感染，例如SARS感染。